Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | -0.21% | 177.13 | 0.7% | $1337.46m | |
| MRK | Merck & Co., Inc. | -0.33% | 90.87 | 0.7% | $1163.98m | |
| PFE | Pfizer Inc. | -1.35% | 51.73 | 0.9% | $1098.82m | |
| LLY | Eli Lilly & Co. | -1.33% | 319.94 | 1.1% | $1031.84m | |
| BMY | Bristol-Myers Squibb Co. | -1.21% | 76.07 | 1.0% | $995.69m | |
| ABBV | AbbVie, Inc. | -0.61% | 152.22 | 1.9% | $952.84m | |
| AZN | AstraZeneca Plc | -1.26% | 65.24 | 1.0% | $435.93m | |
| SGEN | Seagen Inc. | 1.35% | 179.33 | 5.7% | $320.16m | |
| TPTX | Turning Point Therapeutics, Inc. | -0.11% | 75.17 | 0.0% | $287.77m | |
| GSK | GSK Plc | -0.38% | 43.36 | 0.2% | $275.37m | |
| NVS | Novartis AG | -1.04% | 83.65 | 0.2% | $162.86m | |
| HZNP | Horizon Therapeutics Plc | 0.51% | 80.17 | 5.4% | $162.64m | |
| MRTX | Mirati Therapeutics, Inc. | 5.37% | 70.74 | 1.6% | $154.60m | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 1.71% | 148.35 | 8.1% | $142.92m | |
| NVO | Novo Nordisk A/S | -0.77% | 110.57 | 0.1% | $142.12m |
Company Profile
Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, rapid ventricular rate, and other cardiovascular indications. The company was founded by Philippe Douville and Philippe Lamarre in 2003 and is headquartered in Montreal, Canada.